Patent 7144871 was granted and assigned to Cv Therapeutics on December, 2006 by the United States Patent and Trademark Office.
Disclosed are novel compounds that are partial and full A1 adenosine receptor agonists, useful for treating various disease states, in particular tachycardia and atrial flutter, angina, myocardial infarction and hyperlipidemia.